Dyadic to Present at the ThinkEquity Partners 4th Annual Growth Conference on September 14, 2006 at 11:00 a.m. PDT ; Webcast Will Be Available at www.dyadic.com

Business Wire, Sept 8, 2006

JUPITER, Fla. -- Dyadic International, Inc. (AMEX:DIL), a biotechnology company, announced today that Glenn Nedwin, Ph.D, Dyadic's Chief Scientific Officer, Executive Vice President and President of Dyadic's Biosciences Business, will make a presentation at the ThinkEquity Partners 4th Annual Growth Conference to be held at the Ritz Carlton Hotel in San Francisco on September 11-14, 2006. Dr. Nedwin's presentation is scheduled for September 14 at 11:00 a.m. PDT (2 p.m. EDT).

A simultaneous webcast of the presentation may be accessed by clicking the webcast link at http://www.dyadic.com. A replay will be available for 30 days at the same internet address.

Dr. Nedwin plans to discuss the Company's progress in the development of its technologies for the production of new, better and more affordable products in its three core business areas:

--Biorefineries, to communicate the Company's recent advances in the development of its patented and proprietary enzyme mixtures to make abundant low cost sugars from agricultural plant materials (energy crops). Sugars are currently being used to produce ethanol, plastics and polymers to displace petroleum in a variety of manufacturing and refining processes.

--Biosciences, to provide an update on the Company's progress to leverage its C1 Host Technology for use in collaboration with biotech and pharmaceutical companies to enable them to more efficiently discover, develop and produce new, better and more affordable human antibodies and other drugs; and

--Enzymes, to report on the Company's progress in expanding from its historical textile enzyme business to larger and more profitable markets such as pulp and paper and animal feed.

About Dyadic

Dyadic International, Inc., based in Jupiter, Florida, with operations in the United States of America, Hong Kong and mainland China, Poland and The Netherlands, is engaged in the development, manufacture and sale of biological products using a number of proprietary fungal strains to produce enzymes and other biomaterials, principally focused on a system for protein production based on the patented Chrysosporium lucknowense fungus, known as C1. Dyadic is applying its technologies to produce enzymes for use in converting various agricultural products (e.g. corn) and waste products (e.g. switch grass, wheat straw, sugar cane bagasse, etc.) into fermentable sugars, which can then be used in the production of traditional and cellulosic ethanol as well as other products currently derived from petroleum. Dyadic's C1 technology also is being developed to facilitate the discovery, development and large-scale production of human antibodies and other high-value therapeutic proteins. Dyadic currently sells more than 45 liquid and dry enzyme products to more than 200 industrial customers in approximately 50 countries for the textile, pulp & paper, animal feed, alcohol, starch, and food and beverage industries.

Cautionary Statement for Forward-Looking Statements

Certain statements contained in this press release are "forward-looking statements." These forward-looking statements involve risks and uncertainties that could cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. For a discussion of these risks and uncertainties, please see our filings from time to time with the Securities and Exchange Commission, which are available free of charge on the SEC's web site at http://www.sec.gov, including our Annual Report on Form 10-KSB for the year ended December 31, 2005, and our subsequent filings with the SEC. Except as required by law, we expressly disclaim any intent or obligation to update any forward-looking statements.